Avoid common mistakes on your manuscript.
Correction to: Invest New Drugs
https://doi.org/10.1007/s10637-020-00916-3
The article Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, written by Frank Kroschinsky, Jan Moritz Middeke, Martin Janz, Georg Lenz, Mathias Witzens-Harig, Reda Bouabdallah, Paul La Rosée, Andreas Viardot, Gilles Salles, Seok Jin Kim, Tae Min Ki, Oliver Ottmann, Joerg Chromik, Anne-Marie Quinson, Ute von Wangenheim, Ute Burkard, Andreas Berk, Norbert Schmitz, was originally published electronically on the publisher’s internet portal on 14 March 2020 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on May 2020 to © The Author(s) 2020 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The original article has been corrected
Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at https://doi.org/10.1007/s10637-020-00916-3
Rights and permissions
About this article
Cite this article
Kroschinsky, F., Middeke, J.M., Janz, M. et al. Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Invest New Drugs 39, 283–284 (2021). https://doi.org/10.1007/s10637-020-00949-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-020-00949-8